These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

583 related items for PubMed ID: 26329325

  • 1. The safety of calcineurin inhibitors for kidney-transplant patients.
    Malvezzi P, Rostaing L.
    Expert Opin Drug Saf; 2015 Oct; 14(10):1531-46. PubMed ID: 26329325
    [Abstract] [Full Text] [Related]

  • 2. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B, Höcker B.
    Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
    [Abstract] [Full Text] [Related]

  • 3. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C, Suwelack B, Dragun D, Schenker P, Hauser IA, Witzke O, Hugo C, Kamar N, Merville P, Junge M, Thaiss F, Nashan B, Athena Study Group.
    Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM Study.
    Tedesco-Silva H, Pascual J, Viklicky O, Basic-Jukic N, Cassuto E, Kim DY, Cruzado JM, Sommerer C, Adel Bakr M, Garcia VD, Uyen HD, Russ G, Soo Kim M, Kuypers D, Buchler M, Citterio F, Hernandez Gutierrez MP, Bernhardt P, Chadban S, TRANSFORM Investigators.
    Transplantation; 2019 Sep; 103(9):1953-1963. PubMed ID: 30801548
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Rationale and design of the OPTIMIZE trial: OPen label multicenter randomized trial comparing standard IMmunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen In combination with everolimus in de novo renal transplantation in Elderly patients.
    de Boer SE, Sanders JSF, Bemelman FJ, Betjes MGH, Burgerhof JGM, Hilbrands L, Kuypers D, van Munster BC, Nurmohamed SA, de Vries APJ, van Zuilen AD, Hesselink DA, Berger SP.
    BMC Nephrol; 2021 Jun 02; 22(1):208. PubMed ID: 34078323
    [Abstract] [Full Text] [Related]

  • 9. Calcineurin inhibitors in kidney transplantation: friend or foe?
    Casey MJ, Meier-Kriesche HU.
    Curr Opin Nephrol Hypertens; 2011 Nov 02; 20(6):610-5. PubMed ID: 21885969
    [Abstract] [Full Text] [Related]

  • 10. Optimizing the immunosuppressive regimen in heart transplantation.
    Eisen H, Ross H.
    J Heart Lung Transplant; 2004 May 02; 23(5 Suppl):S207-13. PubMed ID: 15093807
    [Abstract] [Full Text] [Related]

  • 11. Calcineurin inhibitor-sparing regimens based on mycophenolic acid after kidney transplantation.
    Kamar N, Del Bello A, Belliere J, Rostaing L.
    Transpl Int; 2015 Aug 02; 28(8):928-37. PubMed ID: 25557802
    [Abstract] [Full Text] [Related]

  • 12. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes.
    Shihab F, Christians U, Smith L, Wellen JR, Kaplan B.
    Transpl Immunol; 2014 Jun 02; 31(1):22-32. PubMed ID: 24861504
    [Abstract] [Full Text] [Related]

  • 13. An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockade.
    Kälble F, Schaier M, Schäfer S, Süsal C, Zeier M, Sommerer C, Morath C.
    Expert Opin Pharmacother; 2017 Jun 02; 18(8):799-807. PubMed ID: 28460546
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Calcineurin inhibitor sparing in renal transplantation.
    Ekberg H.
    Transplantation; 2008 Sep 27; 86(6):761-7. PubMed ID: 18813097
    [Abstract] [Full Text] [Related]

  • 16. Calcineurin inhibitor sparing in paediatric solid organ transplantation : managing the efficacy/toxicity conundrum.
    Tredger JM, Brown NW, Dhawan A.
    Drugs; 2008 Sep 27; 68(10):1385-414. PubMed ID: 18578558
    [Abstract] [Full Text] [Related]

  • 17. The MANDELA study: A multicenter, randomized, open-label, parallel group trial to refine the use of everolimus after heart transplantation.
    Deuse T, Bara C, Barten MJ, Hirt SW, Doesch AO, Knosalla C, Grinninger C, Stypmann J, Garbade J, Wimmer P, May C, Porstner M, Schulz U.
    Contemp Clin Trials; 2015 Nov 27; 45(Pt B):356-363. PubMed ID: 26363128
    [Abstract] [Full Text] [Related]

  • 18. Conversion to Everolimus in Kidney Transplant Recipients With Calcineurin Inhibitor-Induced Nephropathy: 3 Case Reports.
    Nanmoku K, Shinzato T, Kubo T, Shimizu T, Yagisawa T.
    Transplant Proc; 2019 Jun 27; 51(5):1424-1427. PubMed ID: 31060742
    [Abstract] [Full Text] [Related]

  • 19. Calcineurin Inhibitor-Sparing Strategies in Renal Transplantation: Where Are We? A Comprehensive Review of the Current Evidence.
    Camilleri B, Bridson JM, Halawa A.
    Exp Clin Transplant; 2016 Oct 27; 14(5):471-483. PubMed ID: 27213490
    [Abstract] [Full Text] [Related]

  • 20. Calcineurin inhibitors in renal transplantation still needed but in reduced doses: a review.
    Ponticelli C, Scolari MP.
    Transplant Proc; 2010 Oct 27; 42(6):2205-8. PubMed ID: 20692445
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.